Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs?
- 1 May 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 12 (3) , 163-170
- https://doi.org/10.1097/00002281-200005000-00001
Abstract
This has been an unusual year for the accumulation of evidence regarding the clinical effects of inhibition of cyclooxygenase (COX)-1 and COX-2. This article reviews the available data regarding the clinical effects of the new COX-2-specific inhibitors, and speculates about the importance of the data as they relate to the treatment of patients with chronic pain and/or inflammation.Keywords
This publication has 54 references indexed in Scilit:
- Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1999
- NSAIDS, GASTROINTESTINAL INJURY, AND CYTOPROTECTIONGastroenterology Clinics of North America, 1996
- Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: Prophylactic and therapeutic strategiesThe American Journal of Medicine, 1994
- Are There Differences Among Nonsteroidal Antiinflammatory Drugs?Arthritis & Rheumatism, 1994
- Renal complications of nonsteroidal anti-inflammatory drugsKidney International, 1993
- Nonsteroidal Antiinflammatory Drugs and Gastrointestinal Hospitalizations in Saskatchewan: A Cohort StudyEpidemiology, 1992
- Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory DrugsAnnals of Internal Medicine, 1991
- Nonsteroidal Antiinflammatory Drugs — Differences and SimilaritiesNew England Journal of Medicine, 1991
- Nonsteroidal Anti-inflammatory Drug Use and Increased Risk for Peptic Ulcer Disease in Elderly PersonsAnnals of Internal Medicine, 1991
- Toward an Epidemiology of Gastropathy Associated With Nonsteroidal Antiinflammatory Drug UseGastroenterology, 1989